Skip to main content

Aggressive Systemic Mastocytosis clinical trials at UCSF
1 in progress, 0 open to new patients

  • A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies

    Sorry, not currently recruiting here

    This is a Phase 1, open-label, first-in-human (FIH) dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary antitumor activity of DCC-2618, administered orally (PO), in adult patients with advanced malignancies. The study consists of 2 parts, a dose-escalation phase and an expansion phase.

    San Francisco, California and other locations